Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays

Nicholas J Ashton,Albert Puig-Pijoan,Marta Milà-Alomà,Aida Fernández-Lebrero,Greta García-Escobar,Fernándo González-Ortiz,Przemysław R Kac,Wagner S Brum,Andréa L Benedet,Juan Lantero-Rodriguez,Theresa A Day,Jeroen Vanbrabant,Erik Stoops,Eugeen Vanmechelen,Gallen Triana-Baltzer,Setareh Moughadam,Hartmuth Kolb,Paula Ortiz-Romero,Thomas K Karikari,Carolina Minguillon,Juan José Hernández Sánchez,Irene Navalpotro-Gómez,Oriol Grau-Rivera,Rosa María Manero,Víctor Puente-Periz,Rafael de la Torre,Jaume Roquer,Jeff L Dage,Henrik Zetterberg,Kaj Blennow,Marc Suárez-Calvet

DOI: https://doi.org/10.1002/alz.12841

Abstract:Introduction: Direct comparisons of the main blood phosphorylated tau immunoassays in memory clinic populations are needed to understand possible differences. Methods: In the BIODEGMAR study, 197 participants presenting with cognitive complaints were classified into an Alzheimer's disease (AD) or a non-AD cerebrospinal fluid (CSF) profile group, according to their amyloid beta 42/ phosphorylated tau (Aβ42/p-tau) ratio. We performed a head-to-head comparison of nine plasma and nine CSF tau immunoassays and determined their accuracy to discriminate abnormal CSF Aβ42/p-tau ratio. Results: All studied plasma tau biomarkers were significantly higher in the AD CSF profile group compared to the non-AD CSF profile group and significantly discriminated abnormal CSF Aβ42/p-tau ratio. For plasma p-tau biomarkers, the higher discrimination accuracy was shown by Janssen p-tau217 (r = 0.76; area under the curve [AUC] = 0.96), ADx p-tau181 (r = 0.73; AUC = 0.94), and Lilly p-tau217 (r = 0.73; AUC = 0.94). Discussion: Several plasma p-tau biomarkers can be used in a specialized memory clinic as a stand-alone biomarker to detect biologically-defined AD. Highlights: Patients with an Alzheimer's disease cerebrospinal fluid (AD CSF) profile have higher plasma phosphorylated tau (p-tau) levels than the non-AD CSF profile group. All plasma p-tau biomarkers significantly discriminate patients with an AD CSF profile from the non-AD CSF profile group. Janssen p-tau217, ADx p-tau181, and Lilly p-tau217 in plasma show the highest accuracy to detect biologically defined AD. Janssen p-tau217, ADx p-tau181, Lilly p-tau217, Lilly p-tau181, and UGot p-tau231 in plasma show performances that are comparable to their CSF counterparts.